SCHEMBL10375081

SCHEMBL10375081

O=c1c2ccccc2c(Cc2ccc(Cl)cc2)nn1C1CCCN(Cc2ccccc2)CC1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 15/20 0.75
HRH1 P35367 15/20 0.75
ADRA1B P35368 15/20 0.75
HRH3 Q9Y5N1 11/20 0.75
KCNH2 Q12809 5/20 0.75
ADRA2A P08913 2/20 0.75
CHRM1 P11229 2/20 0.75
ADRA2B P18089 2/20 0.75
HTR2A P28223 2/20 0.75
DRD3 P35462 2/20 0.75
ABCB1 P08183 2/20 0.75
CHRM2 P08172 1/20 0.75
ADRB1 P08588 1/20 0.75
CYP2D6 P10635 1/20 0.75
GABRA1 P14867 1/20 0.75
ADRA2C P18825 1/20 0.75
SLC6A2 P23975 1/20 0.75
HTR2C P28335 1/20 0.75
SLC6A4 P31645 1/20 0.75
OPRM1 P35372 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10372558 0.91 ADRA1A (0.79) ADRA1AHRH1ADRA1BHRH3KCNH2
SCHEMBL10555618 0.91 ADRA1A (0.65) ADRA1AHRH1ADRA1BHRH3KCNH2
SCHEMBL10557080 0.91 ADRA1A (0.64) ADRA1AHRH1ADRA1BHRH3KCNH2
Formic Acid SCHEMBL2821267 0.90 ADRA1A (0.68) ADRA1AHRH1ADRA1BHRH3KCNH2
SCHEMBL10554910 0.89 ADRA1A (0.62) ADRA1AHRH1ADRA1BHRH3KCNH2
SCHEMBL2821269 0.89 ADRA1A (0.74) ADRA1AHRH1ADRA1BHRH3KCNH2
SCHEMBL2821905 0.88 ADRA1A (0.86) ADRA1AHRH1ADRA1BHRH3KCNH2
SCHEMBL10372532 0.88 ADRA1A (0.72) ADRA1AHRH1ADRA1BHRH3KCNH2
Hydrochloric Acid SCHEMBL2822217 0.87 ADRA1A (0.76) ADRA1AHRH1ADRA1BHRH3KCNH2
SCHEMBL2823355 0.87 ADRA1A (0.65) ADRA1AHRH1ADRA1BHRH3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220127206-A1 METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2022-04-28 US disclosed
EP-3939954-A1 METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE Otsuka Pharmaceutical Co., Ltd. (JP) 2022-01-19 EP disclosed
CN-113518771-A Method for introducing deuterated lower alkyl into amine part of compound containing secondary amine 大塚制药株式会社 2021-10-19 CN disclosed
WO-2020184670-A1 METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE 大塚製薬株式会社 2020-09-17 WO disclosed
WO-2020184670-A1 METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE 大塚製薬株式会社 2020-09-17 WO disclosed
EP-0174464-B1 SUBSTITUTED BENZYL PHTHALAZINONE DERIVATIVES ASTA Pharma AG (DE) 1990-01-03 EP disclosed
US-4704387-A N-benzyl, phenethyl, methoxyethyl or allyl substituted benzylphthalazinones having antiallergic and antihistamine action ASTA-WERKE AKTIENGESELLSCHAFT, CHEMISCHE FABRIK (DE) 1987-11-03 US disclosed
EP-0174464-A2 Substituted benzyl phthalazinone derivatives ASTA Pharma AG (DE) 1986-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220127206-A1 METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE MGMT, FANCD2, ADAR ADRA1A 2146/4885HRH1 1685/4885ADRA1B 2246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.